Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 8 | 2023 | 93 | 4.510 |
Why?
|
| Rural Population | 2 | 2025 | 373 | 1.370 |
Why?
|
| Physicians | 2 | 2024 | 188 | 1.270 |
Why?
|
| Telemedicine | 2 | 2021 | 234 | 1.040 |
Why?
|
| Pregnancy | 9 | 2023 | 1772 | 0.990 |
Why?
|
| Hawaii | 8 | 2025 | 2011 | 0.930 |
Why?
|
| Abortion, Spontaneous | 2 | 2023 | 27 | 0.920 |
Why?
|
| Perimenopause | 1 | 2025 | 7 | 0.910 |
Why?
|
| Menopause | 1 | 2025 | 64 | 0.880 |
Why?
|
| Mifepristone | 2 | 2021 | 34 | 0.860 |
Why?
|
| Dietary Supplements | 1 | 2025 | 213 | 0.790 |
Why?
|
| Gynecology | 1 | 2023 | 35 | 0.770 |
Why?
|
| Obstetrics | 1 | 2023 | 43 | 0.760 |
Why?
|
| Fetal Research | 1 | 2022 | 4 | 0.750 |
Why?
|
| Contraception | 2 | 2023 | 60 | 0.730 |
Why?
|
| Students, Medical | 1 | 2024 | 158 | 0.700 |
Why?
|
| Abortifacient Agents | 1 | 2021 | 12 | 0.690 |
Why?
|
| Misoprostol | 1 | 2021 | 27 | 0.680 |
Why?
|
| Female | 17 | 2025 | 24698 | 0.620 |
Why?
|
| Menstruation | 1 | 2019 | 11 | 0.610 |
Why?
|
| Medical History Taking | 1 | 2019 | 38 | 0.600 |
Why?
|
| Sex Counseling | 1 | 2019 | 2 | 0.600 |
Why?
|
| Contraception, Postcoital | 1 | 2019 | 8 | 0.600 |
Why?
|
| Social Behavior | 1 | 2020 | 161 | 0.600 |
Why?
|
| Levonorgestrel | 1 | 2019 | 17 | 0.590 |
Why?
|
| Anesthesiology | 1 | 2018 | 7 | 0.590 |
Why?
|
| Women | 1 | 2019 | 28 | 0.590 |
Why?
|
| Sexual Behavior | 2 | 2019 | 638 | 0.520 |
Why?
|
| Humans | 19 | 2025 | 43102 | 0.510 |
Why?
|
| Overweight | 1 | 2019 | 249 | 0.490 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 231 | 0.490 |
Why?
|
| United States | 5 | 2023 | 5205 | 0.370 |
Why?
|
| Adult | 7 | 2025 | 13872 | 0.360 |
Why?
|
| Depression | 1 | 2018 | 863 | 0.350 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2544 | 0.320 |
Why?
|
| Qualitative Research | 2 | 2023 | 574 | 0.310 |
Why?
|
| Specimen Handling | 1 | 2025 | 63 | 0.220 |
Why?
|
| HIV Infections | 1 | 2019 | 2586 | 0.220 |
Why?
|
| Papillomaviridae | 1 | 2025 | 142 | 0.210 |
Why?
|
| Forecasting | 1 | 2024 | 136 | 0.200 |
Why?
|
| Women's Health | 1 | 2024 | 160 | 0.190 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2022 | 4 | 0.190 |
Why?
|
| Aborted Fetus | 1 | 2022 | 5 | 0.190 |
Why?
|
| Neuroblastoma | 2 | 2013 | 136 | 0.190 |
Why?
|
| Religion | 1 | 2023 | 90 | 0.190 |
Why?
|
| Intention | 1 | 2023 | 108 | 0.180 |
Why?
|
| Linear Models | 1 | 2023 | 317 | 0.180 |
Why?
|
| Schools | 1 | 2024 | 283 | 0.180 |
Why?
|
| Abortion, Legal | 1 | 2021 | 6 | 0.170 |
Why?
|
| Aftercare | 1 | 2021 | 22 | 0.170 |
Why?
|
| Guam | 1 | 2021 | 83 | 0.170 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 40 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 449 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 376 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2025 | 367 | 0.160 |
Why?
|
| Young Adult | 2 | 2023 | 5080 | 0.160 |
Why?
|
| Adolescent | 2 | 2023 | 6081 | 0.160 |
Why?
|
| Prevalence | 1 | 2024 | 1612 | 0.150 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 153 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 405 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2018 | 187 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2018 | 146 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 278 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3156 | 0.120 |
Why?
|
| Risk-Taking | 1 | 2019 | 457 | 0.120 |
Why?
|
| Aged | 2 | 2025 | 8214 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 485 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1028 | 0.110 |
Why?
|
| Universities | 1 | 2018 | 559 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2019 | 925 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2013 | 220 | 0.110 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2013 | 1 | 0.100 |
Why?
|
| Middle Aged | 2 | 2025 | 12222 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 165 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 154 | 0.090 |
Why?
|
| Male | 2 | 2023 | 23409 | 0.080 |
Why?
|
| Child | 1 | 2019 | 3443 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 307 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2025 | 259 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 138 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 310 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 2676 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 40 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 39 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 51 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 18 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 129 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 158 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 142 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 120 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 102 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 99 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 257 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 665 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 861 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 780 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 638 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 518 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1568 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 6644 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 16992 | 0.010 |
Why?
|